Skip to main content

Table 4 Effectiveness of 12-week adalimumab treatment in patients with PsA stratified by prior anti-TNF therapy

From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

Outcome measure

No prior ETN/IFX

Prior ETN or IFX or both

 

(n = 376)

(n = 66)

TJC (0 to 78)

  

   Baseline

16

15

 

10, 27

8, 25

   Change, Baseline to week 12

-10

-10

 

-17, -5

-16, -3

SJC (0 to 76)

  

   Baseline

9

7

 

5, 13

5, 11

   Change, Baseline to week 12

-7

-5

 

-10, -3

-8, -3

HAQ DI (0 to 3)

  

   Baseline

1.25

1.44

 

0.75, 1.63

1.00, 1.75

   Change, Baseline to week 12

-0.50

-0.50

 

-0.88, -0.13

-0.75, -0.25

Patients with nail psoriasis (NAPSI ≥ 1)

n = 223

n = 36

NAPSI (0 to 80)

  

   Baseline

14

18

 

5, 30

10, 37

   Change, Baseline to week 12

-6

-6

 

-14, -2

-15, -1

  1. Values are expressed as median and quartile 1, quartile 3. ETN, etanercept; HAQ DI, Health Assessment Questionnaire Disability Index; IFX, infliximab; NAPSI, Nail Psoriasis Severity Index (only fingernails); PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; TNF, tumor necrosis factor.